Topic analysis

Prostate cancer screening only for 'a few thousand' high risk men

The UK National Screening Committee's 2026 final recommendations advise routine prostate cancer screening via PSA blood tests should be limited to only a few thousand high-risk men: those with the BRCA2 genetic variant and a family history of breast, ovarian, pancreatic, or prostate cancer, as screening for all other groups causes more harm than benefit including unnecessary treatment leading to incontinence and sexual dysfunction. Final implementation decisions rest with devolved UK health ministers; Prostate Cancer UK has criticized the recommendations as overly restrictive, while the committee plans to evaluate emerging evidence to potentially expand eligibility in future.